Overview

• Oncology company's Q4 revenue slightly missed analyst expectations

• Adjusted net income for Q4 beat analyst estimates

• Company completed $500 mln stock repurchase program, authorized additional $750 mln buyback

Outlook

• Exelixis maintains 2026 revenue guidance at $2.525 bln - $2.625 bln

• Company expects net product revenues of $2.325 bln - $2.425 bln in 2026

• Exelixis anticipates key clinical readouts from STELLAR-303 and -304 trials in 2026

Result Drivers

• CABOZANTINIB DEMAND - Strong demand in renal cell carcinoma and neuroendocrine tumors drove significant increase in net product revenues

• GI SALES TEAM EXPANSION - Co expedited buildout of GI sales team to accelerate cabozantinib's growth and prepare for future indications

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Exelixis Inc is $47.00, about 6.9% above its February 9 closing price of $43.95

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nBw8FSBYwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)